advertisement
Yao K 16
Showing records 1 to 16 | Display all abstracts from Yao K105049 Covalent Organic Framework (COF): A Drug and Carrier to Attenuate Retinal Ganglion Cells Death in an Acute Glaucoma Mouse Model
Yao K
Polymers 2022; 14:
104851 Effectiveness and safety of tafluprost in primary open-angle glaucoma and ocular hypertension: a post-marketing phase IV study in China
Sun X
BMC Ophthalmology 2022; 22: 332
105049 Covalent Organic Framework (COF): A Drug and Carrier to Attenuate Retinal Ganglion Cells Death in an Acute Glaucoma Mouse Model
Liang X
Polymers 2022; 14:
104851 Effectiveness and safety of tafluprost in primary open-angle glaucoma and ocular hypertension: a post-marketing phase IV study in China
Liu Q
BMC Ophthalmology 2022; 22: 332
105049 Covalent Organic Framework (COF): A Drug and Carrier to Attenuate Retinal Ganglion Cells Death in an Acute Glaucoma Mouse Model
Zhang G
Polymers 2022; 14:
104851 Effectiveness and safety of tafluprost in primary open-angle glaucoma and ocular hypertension: a post-marketing phase IV study in China
Tang X
BMC Ophthalmology 2022; 22: 332
105049 Covalent Organic Framework (COF): A Drug and Carrier to Attenuate Retinal Ganglion Cells Death in an Acute Glaucoma Mouse Model
Rong Y
Polymers 2022; 14:
104851 Effectiveness and safety of tafluprost in primary open-angle glaucoma and ocular hypertension: a post-marketing phase IV study in China
Yao K
BMC Ophthalmology 2022; 22: 332
105049 Covalent Organic Framework (COF): A Drug and Carrier to Attenuate Retinal Ganglion Cells Death in an Acute Glaucoma Mouse Model
Zhang Q
Polymers 2022; 14:
104851 Effectiveness and safety of tafluprost in primary open-angle glaucoma and ocular hypertension: a post-marketing phase IV study in China
Li Y
BMC Ophthalmology 2022; 22: 332
105049 Covalent Organic Framework (COF): A Drug and Carrier to Attenuate Retinal Ganglion Cells Death in an Acute Glaucoma Mouse Model
Liao Q
Polymers 2022; 14:
104851 Effectiveness and safety of tafluprost in primary open-angle glaucoma and ocular hypertension: a post-marketing phase IV study in China
Yang J; Zhang M
BMC Ophthalmology 2022; 22: 332
105049 Covalent Organic Framework (COF): A Drug and Carrier to Attenuate Retinal Ganglion Cells Death in an Acute Glaucoma Mouse Model
Zhang H; Xi K
Polymers 2022; 14:
104851 Effectiveness and safety of tafluprost in primary open-angle glaucoma and ocular hypertension: a post-marketing phase IV study in China
Yuan H; Zheng Y
BMC Ophthalmology 2022; 22: 332
105049 Covalent Organic Framework (COF): A Drug and Carrier to Attenuate Retinal Ganglion Cells Death in an Acute Glaucoma Mouse Model
Wang J
Polymers 2022; 14:
104851 Effectiveness and safety of tafluprost in primary open-angle glaucoma and ocular hypertension: a post-marketing phase IV study in China
Li W; Peng H
BMC Ophthalmology 2022; 22: 332
